Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Pro Medicus Limited ( (AU:PME) ).
Pro Medicus Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on its website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, demonstrating its commitment to transparency and accountability. This announcement is significant as it highlights Pro Medicus’s dedication to maintaining high governance standards, which is crucial for its reputation and trust among stakeholders.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging software and services to healthcare professionals. The company focuses on delivering innovative solutions for medical imaging and healthcare IT systems, aiming to enhance diagnostic capabilities and streamline clinical workflows.
Average Trading Volume: 172,667
Technical Sentiment Signal: Buy
Current Market Cap: A$31.67B
For a thorough assessment of PME stock, go to TipRanks’ Stock Analysis page.